AKT-AMPKα-mTOR-dependent HIF-1α Activation is a New Therapeutic Target for Cancer Treatment: A Novel Approach to Repositioning the Antidiabetic Drug Sitagliptin for the Management of Hepatocellular Carcinoma

• Egile Nagusiak: Eslam E. Abd El-Fattah (Egilea), Sameh Saber (Egilea), Mahmoud E. Youssef (Egilea), Hanan Eissa (Egilea), Eman El-Ahwany (Egilea), Noha A. Amin (Egilea), Mohammed Alqarni (Egilea), Gaber El-Saber Batiha (Egilea), Ahmad J. Obaidullah (Egilea), Mohamed M.Y. Kaddah (Egilea), Ahmed Gaafar Ahmed Gaafar (Egilea), Ahmed A.E. Mourad (Egilea), Gomaa Mostafa-Hedeab (Egilea), Amir Mohamed Abdelhamid (Egilea)
• Formatua: Liburua
• Argitaratua: Frontiers Media S.A., 2022-01-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

HIF-1α is a key factor promoting the development of hepatocellular carcinoma (HCC). As well, AKT-AMPKα-mTOR signaling is a promising target for cancer therapy. Yet, the AKT-AMPKα-mTOR-dependent activation of HIF-1α has not been studied in livers with HCC. In addition, the mechanisms underlying the p...